Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
A person named Johanna Mercier has filed to sell up to 28,000 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $4,324,227.70, on or about 02/17/2026 on the NASDAQ market.
The shares to be sold include 25,000 shares acquired via a stock option exercise for cash on 02/17/2026 and 3,000 restricted shares acquired on 03/10/2024. Over the prior three months, Mercier sold 3,000 shares on 01/15/2026 for $372,930.00 and another 3,000 shares on 12/15/2025 for $366,000.00.
GILD insider Andrew Dickinson has filed a Form 144 to potentially sell 3,000 shares of common stock. The planned sale is to be executed through Morgan Stanley Smith Barney on NASDAQ around February 17, 2026, with an indicated aggregate market value of $463,290.
The 3,000 shares were acquired as performance shares from the issuer on January 24, 2023. Over the past three months, Dickinson has already sold 3,000 common shares on December 15, 2025 for $366,000 and another 3,000 shares on January 15, 2026 for $372,930.
Gilead Sciences executive Keeley M. Cain Wettan, EVP Gen Counsel, Legal & Comp, filed an initial ownership report showing direct holdings in Gilead Sciences, Inc. common stock and equity awards as of February 4, 2026. The filing lists 3,944 shares of common stock, restricted stock units covering 5,440 and 11,342 shares, and several non-qualified stock options with exercise prices from $57.92 to $117.21 and expirations between 2032 and 2035. The restricted stock units and options vest over three- or four-year schedules, with portions vesting on the first anniversary of grant and the remainder vesting quarterly or annually until fully vested.
Gilead Sciences filed a Form 13F Holdings Report disclosing its institutional holdings. The filing lists 6 reported holdings with a combined market value of $1,935,507,854. The report was signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, on 02-12-2026.
Gilead Sciences reported higher fourth quarter and full-year 2025 results, driven mainly by its HIV and liver disease portfolios. Q4 2025 revenue rose 5% to $7.9 billion, and diluted EPS increased to $1.74. Full-year 2025 revenue grew 2% to $29.4 billion, with diluted EPS jumping to $6.78 from $0.38, helped by lower IPR&D charges, higher product sales and lower SG&A.
Product sales excluding Veklury increased 4% to $28.0 billion in 2025. HIV sales grew 6% to $20.8 billion, including Biktarvy up 7% to $14.3 billion and Descovy up 31% to $2.8 billion. Liver disease sales rose 6% to $3.2 billion, while Veklury declined 49% to $911 million as COVID-19 hospitalizations fell.
Non-GAAP diluted EPS for 2025 was $8.15, up from $4.62, reflecting strong underlying profitability. Gilead generated $10.0 billion in operating cash flow during 2025, maintained product gross margin near 78% on a GAAP basis and 86% on a non-GAAP basis, and ended the year with $10.6 billion in cash, cash equivalents and marketable debt securities.
For full-year 2026, Gilead projects product sales of $29.6–$30.0 billion, including Veklury of $600 million, and diluted EPS of $6.75–$7.15, with non-GAAP diluted EPS of $8.45–$8.85. The company highlighted continued launches such as Yeztugo for HIV prevention and Livdelzi for liver disease, as well as planned oncology and HIV pipeline launches.
Gilead Sciences chairman and CEO Daniel P. O'Day reported an automatic insider transaction involving stock options and common shares. On February 5, 2026, he exercised 115,640 non-qualified stock options at a price of $66.01 per share and received the same number of common shares.
That same day, he sold 115,640 shares of Gilead common stock at $150 per share under a Rule 10b5-1 trading plan adopted on February 28, 2025. After these transactions, he directly owned 613,912 shares of Gilead common stock.
Gilead Sciences officer Johanna Mercier, Chief Commercial & Corporate Affairs Officer, reported performance-based stock awards on common shares. On February 3, 2026, she acquired 44,867 shares at $0 following certification that performance goals were met for awards granted in March 2023 and March 2024.
On the same date, 24,800 shares were withheld at $143.28 per share, likely for tax obligations, leaving her with 123,288 shares of Gilead common stock held directly. Portions of the 2024 award will be issued only after additional service requirements are satisfied.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported equity-related transactions in company common stock. On February 3, 2026, he acquired 44,867 shares of common stock at $0 per share, tied to performance share awards granted on March 10, 2023 and March 10, 2024.
These awards vested after the Compensation and Talent Committee certified achievement of performance goals, though shares from the March 10, 2024 grant will only be issued once additional service requirements are met. On the same date, he had a disposition coded "F" of 24,802 shares at $143.28 per share. Following these transactions, Dickinson directly owns 170,568 shares of Gilead common stock.
Gilead Sciences Chairman and CEO Daniel P. O'Day reported equity compensation activity involving the company’s common stock. On February 3, 2026, he acquired 131,675 shares at $0 under performance share awards granted in March 2023 and March 2024 after performance goals were certified.
On the same date, 74,461 shares were disposed of at $143.28, typically reflecting shares withheld to cover taxes on the vesting. After these transactions, O'Day directly owned 613,912 shares of Gilead common stock. Portions of the 2024 performance award will only be issued once additional service-vesting requirements are met.
Daniel O'Day filed to sell 115640 shares of Gilead common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 17346000.00 and 1240679623 Gilead shares outstanding.
The 115640 shares were acquired on 02/05/2026 via a stock option exercise from the issuer, paid in cash on the same date. Over the prior three months, O'Day sold additional Gilead common shares in four trades totaling 145640 shares for gross proceeds of 187627,? wait.